marine drugs

IMPACT FACTOR 4.9 | Indexed in: PubMed | CITESCORE 9.6

an Open Access Journal by MDPI

Marine-derived Bioactive Peptides and Lipids Applied in Non-communicable Diseases

Guest Editor:

Dr. Constantina Nasopoulou
Laboratory of Food Chemistry—Technology and Quality of Food of Animal Origin, Department of Food Science and Nutrition, School of the Environment, University of the Aegean, Metropolite Ioakeim 2, 81400 Myrina, Lemnos, Greece

Deadline for manuscript submissions:
closed (30 November 2018)

Message from the Guest Editor

Dear Colleagues,

Non-communicable diseases, such as cardiovascular diseases, different types of cancer, respiratory diseases and diabetes, are the leading cause of death globally. Marine species are valuable source of bioactive constituents, such as peptides, proteins and lipids. Marine-derived biopeptides—due to their structural properties and their amino acids composition and sequences - exhibit various biological activities such as anti-atherosclerotic, anti-hypertensive, anti-cancer, anti-diabetic, anti-oxidative, anti-obesity activity, etc., preventing non-communicable diseases. Additionally, marine-derived bioactive lipids such as marine phosholipids have high content of the long-chain polyunsaturated omega-3 fatty acids EPA and DHA and exhibit numerous biological properties against atherosclerosis, thrombosis and inflammation. Therefore, the purpose of the current Special Issue is to publish novel ideas related to the therapeutic potential of marine-derived bioactive peptides and lipids in the treatment or prevention of non-communicable diseases.

Dr. Constantina Nasopoulou
Guest Editor

marine drugs

IMPACT FACTOR 4.9 | Indexed in: PubMed | CITESCORE 9.6

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker
Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

Contact Us

Marine Drugs Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
𝕏@Marine_Drugs